Gradient Investments LLC Takes Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Gradient Investments LLC has acquired a new stake in Thermo Fisher Scientific, purchasing 5,168 shares valued at approximately $2,095,000 during the 2nd quarter.
• Thermo Fisher Scientific received positive analyst ratings with UBS Group increasing its price target from $460 to $500, and Barclays raising its rating from "equal weight" to "overweight" with a new target of $550.
• The company's recent quarterly earnings exceeded expectations, reporting $5.36 earnings per share and a revenue of $10.86 billion, reflecting a year-over-year increase of 2.9%.

Gradient Investments LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,168 shares of the medical research company's stock, valued at approximately $2,095,000.

Several other large investors have also made changes to their positions in TMO. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth $30,000. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth $30,000. Finally, Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth $31,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $592.24.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.0%

TMO stock opened at $474.73 on Tuesday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company's 50 day moving average is $467.98 and its two-hundred day moving average is $450.20. The stock has a market cap of $179.26 billion, a P/E ratio of 27.46, a PEG ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.